161 related articles for article (PubMed ID: 38012675)
21. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation.
Wang D; Yin Y; Zhou Q; Li Z; Ma X; Yin Y; Li B; Bai T; Li D; Zhu J
Med Phys; 2022 Jan; 49(1):756-767. PubMed ID: 34800297
[TBL] [Abstract][Full Text] [Related]
23. Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity.
Vandecasteele K; Tummers P; Makar A; van Eijkeren M; Delrue L; Denys H; Lambert B; Beerens AS; Van den Broecke R; Lambein K; Fonteyne V; De Meerleer G
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):408-14. PubMed ID: 22377596
[TBL] [Abstract][Full Text] [Related]
24. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
[TBL] [Abstract][Full Text] [Related]
25. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
26. The volume of
Wang SB; Liu JP; Lei KJ; Jia YM; Xu Y; Rong JF; Wang CX
Cancer Med; 2019 Dec; 8(17):7219-7226. PubMed ID: 31621208
[TBL] [Abstract][Full Text] [Related]
27. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
[TBL] [Abstract][Full Text] [Related]
28. Evaluating dosimetric parameters predictive of hematologic toxicity in cervical cancer patients undergoing definitive pelvic chemoradiotherapy.
Rahimy E; von Eyben R; Lewis J; Hristov D; Kidd E
Strahlenther Onkol; 2022 Sep; 198(9):773-782. PubMed ID: 35059758
[TBL] [Abstract][Full Text] [Related]
29. Comparison of survival, acute toxicities, and dose-volume parameters between intensity-modulated radiotherapy with or without internal target volume delineation method and three-dimensional conformal radiotherapy in cervical cancer patients: A retrospective and propensity score-matched analysis.
Liang YQ; Feng SQ; Xie WJ; Jiang QZ; Yang YF; Luo R; Kidd EA; Zhai TT; Xie LX
Cancer Med; 2022 Jan; 11(1):151-165. PubMed ID: 34821082
[TBL] [Abstract][Full Text] [Related]
30. Dosimetric correlation of bone marrow irradiation with acute hematological toxicity in concurrent chemoradiation of cervical carcinoma patients.
Pruthi DS; Nagpal P; Pandey M; Singh H
Indian J Cancer; 2023; 60(3):432-438. PubMed ID: 36861701
[TBL] [Abstract][Full Text] [Related]
31. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
32. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
33. A randomized study for dosimetric assessment and clinical impact of bone marrow sparing intensity-modulated radiation therapy versus 3-dimensional conformal radiation therapy on hematological and gastrointestinal toxicities in cervical cancer.
Kapoor AR; Bhalavat RL; Chandra M; Pareek V; Moosa Z; Markana S; Nandakumar P; Bauskar P; Shincy NV
J Cancer Res Ther; 2022; 18(6):1490-1497. PubMed ID: 36412399
[TBL] [Abstract][Full Text] [Related]
34. Pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis.
Zhou P; Zhang Y; Luo S; Zhang S
Radiother Oncol; 2021 Dec; 165():103-118. PubMed ID: 34718055
[TBL] [Abstract][Full Text] [Related]
35. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
[TBL] [Abstract][Full Text] [Related]
36. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
37. The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation.
Zhou YM; Freese C; Meier T; Go D; Khullar K; Sudhoff M; Lamba M; Kharofa J
Clin Transl Oncol; 2018 Jun; 20(6):713-718. PubMed ID: 29076030
[TBL] [Abstract][Full Text] [Related]
38. Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients.
McGuire SM; Bhatia SK; Sun W; Jacobson GM; Menda Y; Ponto LL; Smith BJ; Gross BA; Bayouth JE; Sunderland JJ; Graham MM; Buatti JM
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):228-39. PubMed ID: 27319286
[TBL] [Abstract][Full Text] [Related]
39. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.
Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K
Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282
[TBL] [Abstract][Full Text] [Related]
40. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
